SANA Earnings Date: Nov 5, 2026 (Estimated) — Sana Biotechnology, Inc.
NASDAQ
Updated
When is SANA's next earnings date?
Sana Biotechnology, Inc. (SANA) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.15.
How did SANA do in its last earnings report?
In its most recent report on Aug 11, 2026, Sana Biotechnology, Inc. posted EPS of -$0.22 versus the -$0.15 estimate, a miss of 49.8%. The stock's 1-day post-earnings move was +4.4%.
How much does SANA stock move after earnings?
SANA beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.1% (up or down) in the day after earnings.
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | -0.15 | -0.22 | -49.76% | — | ❌ Miss | +4.43% | +1.94% | -12.19% | |
| 2026-08-10 | Q2 2026 | -0.13 | -0.13 | +0.00% | $0 | ➖ Inline | +4.99% | +1.94% | -12.19% |
| 2026-05-11 | Q1 2026 | -0.15 | -0.14 | +6.67% | $0 | ✅ Beat | -8.43% | -14.61% | -20.79% |
| 2026-03-03 | Q4 2025 | -0.13 | -0.16 | -23.08% | $0 | ❌ Miss | -2.80% | -16.29% | -22.39% |
| 2025-11-06 | Q3 2025 | -0.19 | -0.15 | +21.05% | $0 | ✅ Beat | +0.99% | -9.63% | +14.32% |
| 2025-08-11 | Q2 2025 | -0.21 | -0.16 | +23.81% | $0 | ✅ Beat | +6.51% | +16.44% | -0.34% |
| 2025-03-17 | Q4 2024 | -0.26 | -0.23 | +11.54% | $0 | ✅ Beat | -17.69% | -12.64% | -38.63% |
| 2024-11-08 | Q3 2024 | -0.27 | -0.27 | +0.00% | $0 | ➖ Inline | -3.06% | -16.45% | -14.52% |
Showing last 8 quarters.